Abstract
In the overall scheme of the future development of new drugs for the treatment of breast cancer, specially tamoxifen resistant tumours, we have explored the unprecedented use of organometallic SERMs. The initial idea is to enhance the efficacy of the current standard, i.e. tamoxifen, by modifying the structure through judicious incorporation of an organometallic moiety possessing novel properties. Results have been varied, justifying a systematic approach that has proved to be full of surprised. The following differing situations were observed (a) the anti-proliferative effect is due to the vector and the organometallic moiety does not improve the effects of the SERM, no matter what concentration is used. In particular, this is the case for the hydroxytamoxifen derivative bearing a CpRe(CO)3 group, which behaves almost identically to hydroxytamoxifen. These stable species have future promise for use with radionucleides of Re and Tc (b) the effect of the organometallic moiety counteracts the anti-estrogenic behaviour of the vector and leads to species with proliferative activity; this is the case with Cp2TiCl2 entity, which when attached to tamoxifen behaves as a powerful estrogen, probably due to in situ release of Ti(IV) (c) a synergy exists between the cytotoxic organometallic moiety and its organic vector, leading to unique anti-proliferative effects on breast cancer cells classed ER+ and ER-. This result opens a new window on organometallic oncology. It is also clear that the range of possibilities is broad, varied and currently unpredictable. A systematic study combining organometallic chemistry and biology is the only option in the search for new SERMs with novel properties.
Keywords: bioorganometallic chemistry, ferrocene, metallocene, breast cancer, tamoxifen, serm
Current Medicinal Chemistry
Title: The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer
Volume: 11 Issue: 18
Author(s): Gerard Jaouen, Siden Top, Anne Vessieres, G. Leclercq and Michael J. McGlinchey
Affiliation:
Keywords: bioorganometallic chemistry, ferrocene, metallocene, breast cancer, tamoxifen, serm
Abstract: In the overall scheme of the future development of new drugs for the treatment of breast cancer, specially tamoxifen resistant tumours, we have explored the unprecedented use of organometallic SERMs. The initial idea is to enhance the efficacy of the current standard, i.e. tamoxifen, by modifying the structure through judicious incorporation of an organometallic moiety possessing novel properties. Results have been varied, justifying a systematic approach that has proved to be full of surprised. The following differing situations were observed (a) the anti-proliferative effect is due to the vector and the organometallic moiety does not improve the effects of the SERM, no matter what concentration is used. In particular, this is the case for the hydroxytamoxifen derivative bearing a CpRe(CO)3 group, which behaves almost identically to hydroxytamoxifen. These stable species have future promise for use with radionucleides of Re and Tc (b) the effect of the organometallic moiety counteracts the anti-estrogenic behaviour of the vector and leads to species with proliferative activity; this is the case with Cp2TiCl2 entity, which when attached to tamoxifen behaves as a powerful estrogen, probably due to in situ release of Ti(IV) (c) a synergy exists between the cytotoxic organometallic moiety and its organic vector, leading to unique anti-proliferative effects on breast cancer cells classed ER+ and ER-. This result opens a new window on organometallic oncology. It is also clear that the range of possibilities is broad, varied and currently unpredictable. A systematic study combining organometallic chemistry and biology is the only option in the search for new SERMs with novel properties.
Export Options
About this article
Cite this article as:
Jaouen Gerard, Top Siden, Vessieres Anne, Leclercq G. and McGlinchey J. Michael, The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer, Current Medicinal Chemistry 2004; 11 (18) . https://dx.doi.org/10.2174/0929867043364487
DOI https://dx.doi.org/10.2174/0929867043364487 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases
Current Medicinal Chemistry Mutual Modulation of Femarelle and Vitamin D Analog Activities in Human Derived Female Cultured Osteoblasts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Smart Inulin-Based Polycationic Nanodevices for siRNA Delivery
Current Drug Delivery Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Anti-Proliferative Role of the Tyrosine Kinase Inhibitors TKI-258 on Oral Squamous Cell Carcinoma In Vitro
Anti-Cancer Agents in Medicinal Chemistry Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design From Traditional European Medicine to Discovery of New Drug Candidates for the Treatment of Dementia and Alzheimer's Disease: Acetylcholinesterase Inhibitors
Current Medicinal Chemistry Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Combination of Anti-EGFR Drugs with Anti-Angiogenic or Other Signal Transduction Inhibitors as a Rational Approach to Cancer Therapy
Current Cancer Therapy Reviews Microarray-Based Gene Expression Analysis of Hepatocellular Carcinoma
Current Genomics α<sub>IIb</sub>β<sub>3</sub>-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells
Current Drug Targets A Study of the Mechanism of Binding between Neratinib and MAD2L1 Based on Molecular Simulation and Multi-spectroscopy Methods
Current Pharmaceutical Design Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Metabolomics for Personalized Nutrition Research and Clinical Applications
Current Pharmacogenomics and Personalized Medicine Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry An Active and Low-cost Microwave Imaging System for Detection of Breast Cancer Using Back Scattered Signal
Current Medical Imaging